The COVID-19 adversely impacted the management by Health Systems of breast cancer (BC), the first cause of cancer-related death and the second most diagnosed cancer of women, with up to 30% of metastases after treatment and up to 10% in stage IV.1-30 The main objectives are early diagnosis, prompt treatment, and longstanding care support including coping appropriated positive strategies focusing physical and mental health.15,19 Near 2.3 million new cases were diagnosed in 2020, corresponding to 11.7 % of all cancer diagnoses worldwide, affecting people of all the age groups and causing 685,000 deaths.2 Based on the data of studies from diverse countries, one easily understand the elevated burden imposed by COVID-19 pandemic on BC screening and management.1-14,16-18,20-30 Since January 2022, most studies concluded by a negative association between lockdown restrictions and breast cancer care, including difficult access to healthcare, increased prescription of preoperative endocrine therapy, and delayed surgery beyond 12 weeks.3 The aim is shortly present the conclusions of some articles published from 2021 to 2023.
